TOKYO —

An innovative experimental drug, codenamed DT-109, developed by researchers at Michigan Medicine, has demonstrated remarkable success in reversing a serious form of fatty liver disease in animal studies. The compound achieves this significant therapeutic effect by targeting an unexpected yet crucial source of liver damage: the gut. This groundbreaking approach, detailed in a recent publication in The Journal of Clinical Investigation, offers a promising new avenue for treating metabolic dysfunction-associated steatohepatitis (MASH), a condition that continues to pose a substantial global health challenge.

The Gut-Liver Axis: A Complex Interplay in Disease

MASH, a severe manifestation of fatty liver disease, affects an estimated 7% of the global population. It is characterized by the excessive accumulation of fat within the liver, leading to inflammation and cellular injury. Without effective intervention, MASH can progress relentlessly to cirrhosis, a state of extensive liver scarring, and significantly elevate the risk of liver cancer and ultimate liver failure. While recent years have seen incremental improvements in treatment strategies, truly effective therapies remain limited, underscoring the urgent need for novel approaches.

The underlying mechanism of MASH is complex, but a growing body of research points to a critical connection between the health of the gut and the integrity of the liver, often referred to as the gut-liver axis. This intricate relationship means that disturbances in the gastrointestinal tract can have profound and detrimental effects on liver function.

Unraveling the Mechanism: How Gut Bacteria Fuel Liver Damage

The latest research from Michigan Medicine sheds crucial light on how this damaging cycle is initiated and how DT-109 intervenes. Prior studies by Dr. Eugene Chen’s research team had already established DT-109’s efficacy in improving MASH in animal models. DT-109 is a glycine-based tripeptide, a small molecule composed of three amino acids, the fundamental building blocks of proteins. However, the precise mechanism by which it exerted its protective effects remained an area of intense investigation.

This new research provides that missing explanation. The scientists identified a key contributor to MASH: the overgrowth of specific harmful bacteria within the intestines. In particular, the bacterium Clostridium perfringens was found to proliferate excessively, leading to an increased production of ammonia within the gut.

Normally, the intestinal lining acts as a robust protective barrier, preventing potentially harmful substances produced by gut microbes from entering the bloodstream and traveling to the liver. However, when ammonia levels surge due to bacterial overgrowth, this delicate intestinal barrier can become compromised. As this barrier weakens, toxins and other inflammatory byproducts generated by gut microbes can translocate into the systemic circulation and reach the liver.

Once in the liver, these microbial products can trigger significant inflammation and activate immune responses in ways that exacerbate liver damage. One particularly concerning response involves the overactivation of CD8+ T cells. These immune cells, which are essential for fighting infections and eliminating abnormal cells, can, when dysregulated, contribute significantly to the inflammatory processes driving MASH.

"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," stated Dr. Eugene Chen, the senior author of the study and the Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."

The findings underscore a critical insight: a disease primarily manifesting in the liver can be significantly influenced by events occurring much earlier in the digestive system. This realization has profound implications for how MASH and related liver conditions are understood and treated.

DT-109: A Dual-Action Therapeutic for Gut and Liver Health

Through a series of meticulously designed experiments, the Michigan Medicine researchers elucidated how DT-109 disrupts this destructive cascade. The compound functions by improving the overall intestinal environment and reinforcing the integrity of the gut’s protective barrier.

Across both rodent models and nonhuman primates, DT-109 was observed to effectively reduce the levels of Clostridium perfringens and consequently lower ammonia production within the intestines. These direct impacts on the gut microbiome and its byproducts led to a strengthening of the intestinal lining. This fortification effectively limited the leakage of harmful microbial substances into the body, thereby mitigating their capacity to inflict damage on the liver.

The results were particularly compelling in nonhuman primates, whose liver biology and gut microbial communities bear a closer resemblance to those of humans than those of mice. In these advanced animal models, DT-109 not only reduced liver inflammation but also demonstrably lessened the severity of MASH.

These collective findings strongly suggest that by targeting detrimental processes within the gut, beneficial effects can be achieved in the liver, even though the drug’s primary site of action is within the gastrointestinal tract.

"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," explained Jifeng Zhang, Ph.D., a co-author of the study and research professor of cardiovascular medicine at the U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."

The concept of the gut-liver axis highlights the direct conduit between the intestines and the liver. Nutrients and other substances absorbed from the intestines are transported directly to the liver via the portal vein, making the liver exceptionally vulnerable to alterations in gut bacteria composition and the functionality of the intestinal barrier. By intervening at this critical junction, DT-109 offers a novel strategy to address the underlying inflammatory drivers of liver disease, rather than solely focusing on mitigating damage once it has occurred.

Potential Beyond Fatty Liver Disease: A Broader Therapeutic Horizon

The researchers’ optimism extends beyond the immediate application for MASH. They believe DT-109’s capacity to fortify the intestinal barrier could hold significant therapeutic potential for a range of other conditions characterized by inflammation and metabolic dysfunction.

Previous investigations have already indicated that DT-109 possesses other beneficial properties. Studies in nonhuman primates have shown that the compound can reduce the formation of atherosclerotic plaques, a key factor in cardiovascular disease, and prevent vascular calcification. Atherosclerotic plaques are fatty deposits that build up in artery walls, narrowing them and impeding blood flow, thus increasing the risk of heart attacks and strokes. Vascular calcification, the hardening of arteries due to calcium deposition, further exacerbates cardiovascular risk.

These findings suggest that DT-109 could potentially serve a dual purpose, addressing both liver and cardiovascular health. This is a particularly important prospect, as metabolic disorders frequently affect multiple organ systems concurrently.

Furthermore, the research team is keen to explore whether DT-109 could offer benefits to individuals suffering from inflammatory bowel disease (IBD), a group of chronic gastrointestinal disorders that includes Crohn’s disease and ulcerative colitis. Given that compromised intestinal barrier function is a recognized factor in many gastrointestinal ailments, a treatment that enhances this barrier’s integrity might provide advantages beyond liver protection. However, extensive further research will be necessary to confirm DT-109’s efficacy in these contexts.

The Road Ahead: From Bench to Bedside

Despite the highly encouraging results observed in animal models, it is crucial to emphasize that DT-109 remains an experimental treatment. While its ability to reverse MASH has been robustly demonstrated in preclinical studies, its safety and efficacy in human patients have yet to be established.

The next critical phase of research will involve comprehensive evaluation of the compound, with the ultimate goal of advancing it into human clinical trials. These trials are indispensable for rigorously assessing its safety profile, determining appropriate dosages and administration methods, and ultimately validating its therapeutic potential in individuals afflicted with MASH.

"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," commented Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health – of course we are excited about these developments."

This discovery marks a significant paradigm shift in the scientific approach to fatty liver disease. By focusing on the modulation of harmful gut bacteria and the restoration of the intestinal barrier, researchers are paving the way for therapies that can protect the liver through mechanisms acting primarily outside the organ itself. If future human studies successfully replicate the benefits observed in animal models, DT-109 could emerge as a vital new therapeutic option for patients battling severe fatty liver disease, potentially offering co-benefits for cardiovascular health as well.

Funding and Disclosures

The research leading to these findings was supported by various funding sources, and intellectual property related to DT-109 is managed by the University of Michigan and Diapin Therapeutics. Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are listed as inventors on a patent application titled "Tripeptides and treatment of metabolic, cardiovascular, and inflammatory disorders." Dr. Chen is also an inventor of DT-109. The University of Michigan holds the patent for the compound and has licensed it to Diapin Therapeutics. Both Dr. Chen and the university have an ownership interest in Diapin Therapeutics, which supplied DT-109 for the research and is continuing its development.

Ethical oversight for human studies was provided by Institutional Review Boards at participating sites, including the First Affiliated Hospital of Xi’an Jiaotong University (approval number: XJTU1AF2023LSK330), the Institutional Review Board of Jinan University (approval number: 2016-017), and the University of Hong Kong/Hospital Authority Hong Kong West Cluster (approval number: UW 20-700). All human study protocols, amendments, and informed consent forms received approval.

Animal research protocols involving nonhuman primates were approved by the Laboratory Animal Care Committee of Xi’an Jiaotong University (approval number: 20191278) and the Institutional Animal Care and Use Committee of Spring Biological Technology Development Co., Ltd. (approval number: 201901). These studies adhered to the guidelines set forth in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.